1 Introduction to Caenorhabditis elegans biology

The roundworm *Caenorhabditis elegans* was selected as a simple metazoan model in the early 1960s by Sydney Brenner for pursuing research in developmental biology and neurobiology. Since its introduction as a model organism, *C. elegans* has been widely used to investigate important biological processes most of which have remained essentially unchanged during evolution [1]. *C. elegans* is a free-living, non-parasitic nematode, with a life cycle of 3.5 days at 20°C and a lifespan of about 2–3 weeks under suitable living conditions. The adult is about 1 mm in length and 80 µm in diameter; it feeds on bacteria such as *Escherichia coli* in liquid medium or on agar plates, and can be easily cultivated in large numbers. *C. elegans* has five pairs of autosomes and one pair of sex chromosomes. It has two sexes, hermaphrodites and males; the ratio of sex chromosomes to autosomes determines its sex. A single hermaphrodite produces ~300 progeny by self-fertilization, and more if it mates with males, which arise occasionally at a frequency of 0.1%. Wild-type individuals consist of 959 somatic cells, 302 of which are neurons. The animal body is transparent so it is easy to track cells and follow cell lineages and biological processes [2].

The genome of *C. elegans*, comprising about a hundred million base pairs, is completely sequenced and surprisingly similar to that of humans; it is estimated that 60–80% of the genes have a human counterpart [3]. Viable mutant strains, strains that overexpress a gene or lack a gene function can be efficiently generated and the resulting phenotypes can be rapidly identified [4]. Comprehensive information concerning gene structure, expression patterns, protein–protein interactions, mutant or RNA interference (RNAi) phenotypes and microarray...
data, is available in Wormbase, the online resource for nematode-related information (http://www.wormbase.org/) [5]. Nematode strains can be stored indefinitely in liquid nitrogen allowing large mutant collections and public mutant repositories to be set up. *C. elegans* is amenable to unbiased forward and reverse genetic screens and is particularly susceptible to gene inactivation by RNAi [6, 7]. Due to its value as a research tool, a large set of methods that include advanced high-resolution imaging techniques have been developed.

*C. elegans* has emerged as a powerful experimental system to study the molecular and cellular aspects of human disease *in vivo*. It has been estimated that about 42% of the human disease genes have an ortholog in the genome of *C. elegans*, including those genes associated with Alzheimer's disease (AD), juvenile Parkinson's disease (PD), spinal muscular atrophy (SMA), hereditary nonpolyposis colon cancer, and many others age-related disorders [8–10]. Modeling a human disease in a simple invertebrate, such as *C. elegans*, allows the dissection of complex molecular pathways into their component parts, thus providing a meaningful insight into the pathogenesis of a complex disease phenotype. Here, we survey nematode models of human disease, highlighting recent discoveries that shed light on the molecular mechanisms underlying disease pathogenesis.

## 2 *C. elegans* models of neurodegenerative disorders

Neurodegeneration has a profound effect on human health, yet the mechanisms underlying neuronal injury and death remain unclear. *C. elegans* models of neuronal dysfunction have been established for a number of neurodegenerative diseases, including AD, PD and polyglutamine-expansion disorders. These models typically involve the transgenic expression of human disease genes.

### 2.1 Alzheimer's disease

AD is a progressive neurological disease that results in the irreversible loss of neurons particularly in the neocortex. The brain of AD-affected patients is characterized by the accumulation of intracellular neurofibrillary tangles (NFTs) composed of the microtubule-associated protein tau that stabilizes microtubules when phosphorylated [11] and of extracellular senile plaques primarily composed of β-amyloid peptide (Aβ) [12]. Compelling evidence supports the causative role of Aβ1–42, which derives from the proteolysis of amyloid precursor protein (APP) by β- and γ-secretase, in AD. Similarly, mutations in the tau gene lead to familiar tauopathies.

Autosomal dominant mutations in APP are correlated with rare cases of early-onset AD. Determining the *in vivo* functions of APP is difficult because mammals have an APP gene family containing two APP-related genes. *C. elegans* has a single APP-related gene, apl-1 mapped on the X chromosome. The apl-1 gene is expressed in multiple cell types and is necessary for many developmental processes, including proper molting and morphogenesis. Loss of apl-1 causes larval lethality, which can be rescued by neuronal expression of the extracellular domain of APL-1. Similarly, the overexpression of APL-1 causes defects in movement, brood size and larval viability of transgenic nematodes. The apl-1 overexpression-induced lethality is partially rescued by the reduced activity of sel12, a *C. elegans* homologue of the human γ-secretase gene component presenilin 1, suggesting that SEL-12, like mammalian PS1, regulates the activity of APL-1 either directly or indirectly [13].

*C. elegans* AD models were developed that express Aβ variants under the control of male-specific, body wall muscle-specific and neuronal-specific promoters. Only transgenic lines carrying the unc-54/Alβ1–42 minigene accumulate intracellular Aβ, and show a progressive paralysis beginning in young adulthood. Co-immunoprecipitation studies coupled with mass spectrometry reveal that chaperone-related proteins (two human HSP70, three HSP-16 homologous to αB-crystallin and a putative negative regulator of HSP70 function) interact with Aβ *in vivo*. This interaction is considered as part of a cellular protective response since the overexpression of either HSP-16.2 or a human HSP70 partially suppresses the Aβ-induced paralysis in worms [14]. Heat shock treatment reduces Aβ oligomeric protein and delays paralysis in transgenic Aβ worms, probably through the activation of heat shock proteins regulated by the heat shock transcription factor 1 (HSF-1) [15]. HSF-1 has been coupled to normal ageing and age-related diseases [16]. Previous studies showed that constituents of *Ginkgo biloba* leaf extract (EGB 761 and ginkgolides) delay β-amyloid-induced paralysis in transgenic *C. elegans* [17]. This effect was not additive to protective heat shock, suggesting a shared mechanism of action by the two treatments [15]. Microarray analysis in a transgenic worm strain that accurately expresses a temperature-inducible Aβ1–42 in body wall muscle, reveals that the gene encoding the arsenite-inducible protein (aip-1) is up-regulated as part of a cellular protective response. Worms overexpressing AIP-1 show decreased ac-
cumulation of Aβ42 peptide and attenuated paralysis. The AIP-1 human homologue, AIRAPL, but not AIRAP when expressed under the control of myo-3 promoter also confers protection against Aβ toxicity [18]. Both AIP-1 and AIRAPL contain a predicted farnesylation site known to be critical for the AIP-1-mediated longevity in C. elegans [19]. AIP-1 and AIRAPL enhance at least partially general protein turnover by acting as positive regulators of proteosomal function, and thus protect against Aβ-induced toxicity [18]. The effects of tetracycline and its analogues doxycycline and minocycline on Aβ42-induced toxicity were assayed [20] using the worms expressing a temperature-inducible Aβ1−42 transgene [21]. Tetracyclines successfully protected transgenic worms from the Aβ insult by reducing the concentration of oligomers considered to be responsible for the toxic phenotype. These effects were specific, dose-dependent and not linked to any antibiotic activity. Furthermore, tetracyclines protect Aβ-expressing nematodes from oxidative stress by reducing the superoxide production, suggesting a potential use of these drugs in targeting Aβ aggregates.

2.2 Tauopathies

Abnormal phosphorylation, aggregation and ultimately functional alteration of the main microtubule-associated protein, tau, is the major cause of neurodegenerative disorders known as tauopathies [22, 23]. Tau aggregates are found in AD, Pick’s disease, corticobasal degeneration, Down’s syndrome and frontotemporal dementia with parkinsonism chromosome 17 type (FTDP-17) [24]. The most common tauopathy is AD. To analyze the role of tau modification during AD progression, human tau and a pseudohyperphosphorylated tau (PHP tau; in which ten serine/threonine residues were changed to glutamates), which mimics AD-relevant tau modification, were brought under the control of the promoter also confers protection against Aβ toxicity [18]. Both AIP-1 and AIRAPL contain a predicted farnesylation site known to be critical for the AIP-1-mediated longevity in C. elegans [19]. AIP-1 and AIRAPL enhance at least partially general protein turnover by acting as positive regulators of proteosomal function, and thus protect against Aβ-induced toxicity [18]. The effects of tetracycline and its analogues doxycycline and minocycline on Aβ42-induced toxicity were assayed [20] using the worms expressing a temperature-inducible Aβ1−42 transgene [21]. Tetracyclines successfully protected transgenic worms from the Aβ insult by reducing the concentration of oligomers considered to be responsible for the toxic phenotype. These effects were specific, dose-dependent and not linked to any antibiotic activity. Furthermore, tetracyclines protect Aβ-expressing nematodes from oxidative stress by reducing the superoxide production, suggesting a potential use of these drugs in targeting Aβ aggregates.

2.2 Tauopathies

Abnormal phosphorylation, aggregation and ultimately functional alteration of the main microtubule-associated protein, tau, is the major cause of neurodegenerative disorders known as tauopathies [22, 23]. Tau aggregates are found in AD, Pick’s disease, corticobasal degeneration, Down’s syndrome and frontotemporal dementia with parkinsonism chromosome 17 type (FTDP-17) [24]. The most common tauopathy is AD. To analyze the role of tau modification during AD progression, human tau and a pseudohyperphosphorylated tau (PHP tau; in which ten serine/threonine residues were changed to glutamates), which mimics AD-relevant tau modification, were brought under the control of the

© 2010 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

mine residues. However, the threshold for polyQ aggregation and toxicity is dynamic and age dependent in *C. elegans*. At 3 days of age or less, only worms expressing Q40 or greater exhibit aggregates, while in older animals aggregates appear even in Q33- and Q35-expressing worms [32].

A link between molecular determinants of ageing and aggregation-mediated proteotoxicity was established in *C. elegans*. Polyglutamine toxicity was dependent on the activity of *daf-16*, a forkhead transcription factor of the FOXO family functioning downstream of *age-1* (a phosphoinositide-3 kinase) in the insulin-like signaling pathway [35]. Work on polyQ suppression shows that TOR-2, the worm ortholog of the mammalian torsinA, is an endoplasmic reticulum (ER)-associated protein with chaperone activity that suppresses polyglutamine aggregation in *C. elegans* [36].

HD is the most frequent autosomal dominant inherited polyQ disorder caused by an expansion of a CAG trinucleotide sequence in the huntingtin (Htt) protein. Normal Huntington alleles encode up to 37 CAG repeats, whereas HD-affected individuals have more than 40.

Previous work has shown that ubiquilin is an interactor of presenilin, a protein associated with AD. Ubiquilin proteins contain multiple ubiquitin-related domains and are linked to the ubiquitin-proteasome system of protein degradation as both their ubiquitin-like domain and the ubiquitin-associated domain have been shown to bind the proteasomal subunit S5a [37]. The role of ubiquilin in HD pathogenesis was investigated using *C. elegans* expressing GFP-Htt-polyQ fusion proteins in body wall muscle. Transgenic worms display a polyQ-length-dependent motility defect that is suppressed by ubiquilin overexpression through an mRFP-tagged ubiquilin fusion protein. Conversely, knockdown by RNAi of *C. elegans* ubiquilin gene exacerbated the motility defect associated with the expression of GFP-Htt (Q55) fusion protein. These findings show that, similar to AD, ubiquilin protects against polyglutamine-induced toxicity, and they suggest a general role for ubiquilin in regulating a number of different neurodegenerative disorders [38].

Two different *C. elegans* models of human disease were used to explore the effects of dietary restriction (DR) on polyglutamine-associated age-related diseases. An HD model in which 35 glutamine residues were fused to YFP (Q35YFP) and expressed in the body wall muscles [32], and a transgenic model expressing a 42-amino acid Aβ (Aβ42) under the control of the *unc-54* promoter, were used in this investigation [40]. The results demonstrate that DR suppresses age-associated paralysis in these worms. To test if DR acts as a general suppressor of proteotoxicity, the effects of food depri-
viation on transgenic worms expressing an aggregation-prone form of GFP (GFP-degron) were also examined. It was shown that both environmental and genetic (represented by the RNAi inhibition of eat-2 and the knockout of rab-10, sams-1 or drr-1 genes that act downstream of food consumption) models of DR confer protection against proteotoxicity in C. elegans. Compelling evidence was presented that the general protective effect of DR is mediated by the activity of the heat shock transcription factor, hsf-1 [41].

2.4 Parkinson’s disease

PD is the second most common neurodegenerative disorder characterized by involuntary movements including bradykinesia and difficulty in balance and muscle rigidity due to the progressive loss of dopaminergic (DA) neurons from the substantia nigra. At the cellular level, PD is characterized by cytoplasmic protein inclusions called Lewy bodies, which are the pathological feature of PD and other neurodegenerative disorders known as synucleopathies [42]. α-Synuclein (α-syn), a major constituent of Lewy bodies, is causatively related to PD since missense mutations in the α-syn gene or duplications and triplications of the α-syn locus cause familiar forms of PD [43–45]. Sporadic PD affecting 1–4% of those over 65 years of age appears to be unrelated to mutations or multiplications of the α-syn locus, and implicates a combination of environmental factors. How α-syn inclusions are formed and how these are linked to disease are poorly understood. Synucleopathies have been associated with mitochondria dysfunction, defective autophagy, impairment of the ubiquitin-proteasome system, production of reactive oxygen species (ROS), and stress within the ER [46].

The worm genome includes orthologs of all established familiar PD genes (Parkin, DJ-1, PINK1, UCHL-1, LRRK2, PARK9 and NURR1) except the α-syn. A transgene bearing Rab1 guanosine triphosphate, a GTPase involved in transport from the ER to Golgi, under the control of the dopamine transporter (DAT-1) gene promoter was used to drive the expression of Rab1 along with α-syn in DA neurons in a worm PD model. Human α-syn overexpression in C. elegans leads to the formation of misfolded α-syn aggregates that increase with age. Coexpression of Rab1 significantly rescued the neurodegeneration caused by the expression of α-syn alone. Considering that Rab1 plays an essential role in ER-Golgi vesicle trafficking and its enhanced expression protects against α-syn pathology, these combined results indicate that the accumulation of α-syn inhibits the ER-Golgi trafficking [47]. Once coexpressed, TOR-2 [48] ameliorated the formation of these aggregates by associating with α-syn in Lewy bodies [49].

Worms expressing both α-syn::GFP and TOR-2 in body wall muscles were used in a large-scale RNAi screen for modifiers of α-syn misfolding and neurodegeneration. In all, 868 candidate genes potentially associated with existing PD genes and pathways were targeted for knockdown; 20 gene products that enhance misfolding of human α-syn upon depletion were isolated. The neuroprotective genes, F32A6.3 (the C. elegans ortholog of VPS41, a conserved vesicular protein, essential for lysosomal biogenesis), W08D2.5 (the worm ortholog of PARK9), and F55A4.1 (ortholog of Sec22p, a well characterized vesicular trafficking protein in yeast), were among those identified. The identification of C. elegans ATG7 as a neuroprotective gene indicates the significant role of autophagy and lysosomal function in preventing the DA neuron loss caused by excess α-syn [48]. To further characterize the processes involved in inclusion body formation, a genome-wide RNAi screen was performed in transgenic worms expressing the α-synuclein-YFP chimera driven by the unc-54 promoter. The screen identified 80 suppressors, of which 49 have an established human ortholog. Most of the genes are involved in protein quality control and vesicle trafficking between the ER-Golgi as well as other vesicular compartments. Moreover, this screen uncovered several regulators of lifespan (the NAD+-dependent protein deacetylase sir-2.1, the sphingolipid synthase lagr-1) as modifiers of inclusion formation, suggesting a link between the molecular mechanisms of ageing and α-syn pathology [50].

Mutations in GTPase (R1441C/G) and kinase (G2019S) domains of leucine-rich repeat kinase (LRRK2) are the most frequent cause of autosomal dominant and idiopathic PD [51, 52]. Expression of human LRRK2 in C. elegans neurons modifies the response to mitochondrial inhibition, inferred by the increased survival of worms exposed to rotenone or paraquat, which are agents that impair mitochondrial function. These findings demonstrate the power of the nematode as a model to study the possible gain-of-function phenotype acquired by LRRK2 mutations. lrk-1 is the sole C. elegans ortholog of LRRK2. lrk-1 and LRRK2 seems to share similar functions since LRRK2 complements the sensitization to rotenone caused by the lrk-1 knockdown. These results indicate a role for LRRK2 and its worm ortholog in regulating mitochondrial dysfunction [53]. R1441C/G and G2019S mutations increase kinase activity of LRRK2 in vitro [54, 55]. The role of LRRK2 in PD pathogenesis
was investigated in vivo using transgenic *C. elegans* overexpressing human LRRK2 wild type, R1441C/G and G2019S mutations and a LRRK2-inactive mutation K1347A in DA neurons. All transgenic worms show an age-dependent degeneration of DA neurons, locomotor dysfunction, behavioral abnormalities and dopamine deficiency. In contrast, loss of endogenous LRK-1 and the GTP-binding defective mutation, K1347A, ameliorated LRRK2-associated phenotypes [56].

2.5 Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS), the most common motor neuron disorder, is characterized by dysfunction or death of motor neurons in the motor cortex, brain stem and spinal cord. Approximately 10% of ALS cases are familiar with an autosomal dominant inheritance [57] and ~20% of familiar ALS (FALS) are associated with mutations in the gene coding for Cu/Zn superoxide dismutase (SOD1) [58], which catalyzes the conversion of highly reactive superoxide anions into hydrogen peroxide [59]. While it is accepted that toxic gain-of-function mutations in SOD1 gene evoke the disease phenotype, the mechanisms of toxicity remain unclear.

Transgenic *C. elegans* expressing FALS-related mutant (A4V, G37R, G93A) human SOD1 are more sensitive to paraquat-induced oxidative stress than control worms expressing wild-type human SOD1. Moreover, the transgenic worms that harbor gain-of-function alleles show an aberrant accumulation and aggregate formation of mutant proteins under oxidative stress. Thus, oxidative damage during ageing might cause FALS by inhibiting degradation and enhancing aggregate formation of mutant SOD1 proteins [60].

G85R, an ALS-associated human mutant SOD1, causes a severe locomotor defect in transgenic *C. elegans* when expressed pan-neuronally under the control of the synaptobrevin (*snb-1*) gene promoter. Paralyzed animals have soluble oligomers and insoluble aggregates in neurons. The movement defect results from the dysfunction of synapses, the connections between neurons and between neurons and muscles. An RNAi screen identified molecular chaperones as critical modifiers of protein aggregation-mediated toxicity [61]. Expression of three distinct SOD1 mutations (G85R, G93A, 127X) in the body muscle cells of wild-type (N2) worms causes only mild cellular toxicity. However, when SOD1 mutants are expressed on the background of destabilized protein polymorphisms, their toxicity is enhanced. These results suggest that the genetic background may intensify the specific toxic pheno-
the mechanisms underlying the disease pathogenesis are poorly understood. Given that SMN is widely expressed both within and outside the nervous system [73], the specific motor neuron defect that the SMA patients face may be rather linked to the gene function [74]. C. elegans smn-1 gene has been identified as the ortholog of human SMN [75] with a widespread expression in various tissues including the nervous system and body wall muscles. The mutant smn-1 (ok355) harbors a deletion allele that removes most of the smn-1, including the translational start codon. Having reduced SMN-1 levels throughout the organism, smn-1 (ok355) is used for modeling aspects of SMA. Mutant animals proceed through embryogenesis due to maternally contributed SMN-1, but showed late larval arrest, decreased lifespan, defects in motility and pharyngeal pumping. Neuronal, but not muscle-directed expression of full-length smn-1 partially rescues the smn-1 (ok355) phenotype [76]. A genome-wide RNAi screen and behavioral studies in the loss of function smn-1 (ok355) mutant strain provide preliminary evidence that the TGF-β/BMP signaling pathway plays a role in the SMN-mediated neuromuscular pathology in C. elegans [77].

3 Stroke – Excitotoxicity

Necrotic cell death underlies the pathology of numerous human degenerative conditions [78]. In C. elegans, non-apoptotic cell death (necrosis) is triggered by specific genetic lesions or environmental conditions such as energy depletion, toxin exposure or extreme temperatures. Severe deprivation of energy resources can rapidly develop during ischemic or hypoglycemic episodes. Prolonged hypoxia, a condition of oxygen deprivation that takes place in ischemic episodes and stroke, also induces cell death in C. elegans [79]. The most thoroughly characterized necrosis-induced mutations in the nematode are gain-of-function mutations in specific ion channel genes, such as degenerin genes deg-1 and mec-4, the acetylcholine receptor channel subunit gene deg-3 and the Gs protein a-subunit gene gsa-1, which result in necrotic cell death of neurons expressing the mutant proteins [80]. Execution of necrotic cell death requires the activity of calcium-regulated CLP-1 and TRA-3 calpain proteases and ASP-3 ASP-4 aspartyl proteases. Perturbation of intracellular concentrations of calcium, either by extracellular calcium influx or by release of ER stores, activates calpain proteases, which in turn engage executioner aspartyl proteases leading to cell destruction [81]. In mammalian models of excitotoxicity, calpains increase Ca\(^{2+}\) concentration by mediating the cleavage of specific glutamate receptors [82]. Aspartyl proteases are either cytoplasmic or lysosomal, being released into the cytoplasm as a result of lysosomal rupture. Acidification of the cytoplasm due to the action of hydrolytic enzymes liberated during the lysosomal rupture requires the vacuolar H\(^{+}\)-V-ATPase (V-ATPas), a proton pump that acidifies endocytic compartments. Similar mechanisms may underlie the extreme acidosis that is observed during stroke in humans [83]. Evidence suggests that lysosomes contribute to execution of necrosis. Suppression of lysosome biogenesis and of lysosome-mediated cytoplasmic acidification, which develops during necrosis and is required for cell death, affects necrosis in C. elegans [84]. A working model for necrotic cell death and cellular defense pathways such as autophagy that may underlie diverse aspects of development, tissue homeostasis and disease pathogenesis in C. elegans is outlined in Fig. 2.

4 Muscle-associated disorders

Dystrophin is a huge cytosolic protein that links the intracellular F-actin filaments to the members of the dystrophin-glycoprotein complex (DGC) [85, 86]. Genetic defects in the complex components cause a variety of pathological conditions, including muscular dystrophy, cardiomyopathy and vasospasm. Determining the molecular function of the complex will increase our understanding of muscle diseases pathogenesis. C. elegans has a dystrophin complex (DAPC) and mutations in its components result in head bending and hypercontraction [87, 88]. Several lines of evidence couple defects in the DAPC with calcium homeostasis disruption through a mechanism involving the ISLO-1, which mediates the interaction of SLO-1 (the ortholog of the mammalian BK channel) with DAPC. A defect in either DAPC or ISLO-1 impacts SLO-1 channel localization resulting in muscle hyperactivity [89].

4.1 Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is one of the most severe X-linked childhood diseases, characterized by progressive muscle wasting and weakness due to mutations in the dystrophin gene [90]. A C. elegans DMD model carrying mutations in dys-1 and hih-1, the worm orthologs of the human dystrophin and MyoD, respectively, was used to investigate the effects of chn-1 on muscle degeneration. chn-1 encodes the homolog of the human E3/E4 ubiquitylation enzyme CHIP (C terminus of Hsc-70
interacting protein) that is strongly expressed in both neurons and muscles [91]. Down-regulation of chn-1 by mutation, as well as by pharmacological treatment with a proteosomal inhibitor (MG132) improves the motility of DMD worms. Muscle-specific decrease of CHN-1 activity is sufficient to control muscle degeneration in dystrophin mutant animals. These data suggest a specific role of CHN-1/CHIP in the control of muscle degeneration through the ubiquitin-proteasome pathway [92].

4.2 Oculopharyngeal muscular dystrophy

Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant myopathy characterized by eyelid ptosis, dysphagia and limb-girdle
of animal development. Work in highly conserved and interfaces with many aspects nicotine [105].

phenotypes that were intensified upon exposure to tion defects, low fecundity and vulval hyperplasia, context. Mutant transgenic worms show locomo-

vestigate cancer gene function in a whole organism mutants (R988C and T1010I) were generated to in-

or the frequent human lung cancer specific c-Met cancer [104] cases, respectively .

cancer [103] and in non-small cell lung cancer [104] cases, respectively.

Transgenic worms expressing wild-type c-Met or the frequent human lung cancer specific c-Met mutants (R988C and T1010I) were generated to in-

vestigate cancer gene function in a whole organism context. Mutant transgenic worms show locomo-

tion defects, low fecundity and vulval hyperplasia, phenotypes that were intensified upon exposure to nicotine [105].

The RTK/Ras/Raf/MAPK signaling pathway is highly conserved and interfaces with many aspects of animal development. Work in C. elegans has greatly contributed in our understanding of this pathway and its regulation [106]. In C. elegans, Ras controls vulval induction and its hyperactivation interferes with vulval cell differentiation, leading to a multivulval phenotype [107]. Vulval development provides a model system to understand cell proliferation and differentiation, deregulation of which is causatively linked to human tumors.

Recently, the role of microRNAs (miRNAs) in human cancer has been extensively studied. miRNAs are small non-protein coding RNA molecules of ~21–23 nucleotides, which control gene expression at the post-transcriptional level acting as developmentional timing regulators [108]. Many of the 112 miRNAs identified so far in C. elegans are conserved across phylogeny. Compelling evidence suggests that miRNAs are involved in the regulation of ageing and metabolism and provides insight into their function as tumor suppressor genes or onco-

genes.

Several miRNAs act in the Notch and Ras signaling pathways [109–111]. miR-84, a let-7 family miRNA, targets let-60, a C. elegans ortholog of HRAS, KRAS and NRAS, the human ras oncogenes. All of the human ras genes have complementary sites for human let-7 family miRNAs in their 3’UTRs, suggesting a similar mode of regulation to that of the worm let-60 [110]. Gain-of-function mutations in let-60 result in a multivulval phenotype that is partially suppressed by mir-84 overexpression [112]. Accumulating evidence suggests that let-7 acts as a tumor suppressor gene. Similarly, miR-61, which targets vav-1, a homologue of the Vav oncogene family in vertebrates [113], may influence cancer through the regulation of Notch signaling [111].

The role of apoptosis in cancer treatment sensitivity is well established. Apoptosis is a genetically regulated cell death mechanism that is required for normal development and homeostasis. Defects in key apoptotic proteins can interfere with tumorige-

ness and chemotherapy [114]. Therefore, understand-

ing the events that affect DNA damage-in-

duced apoptosis at the molecular level is important for cancer research. The apoptotic molecular path-

way is highly conserved [115].

In C. elegans, germline apoptosis limits the number of oocytes competing for nutrients in the gonad. It can also be activated in response to path-

ogenic microorganism invasion or DNA-damaging agents and genotoxic stress [116]. The p53/CEP-1, CED-9 (Bcl-2), CED-4 (ApafI) and CED-3 (caspase) proteins function in the checkpoint machinery of DNA damage-induced germline apoptosis. A recent study revealed that the hypoxia-inducible transcription factor (HIF-1) antagonizes the function of CEP-1 in DNA-damage induced apoptosis. HIF-1 inhibits apoptosis by transcriptionally up-

regulating the tyrosinase family member TYR-2 in the ASJ neurons. TYR-2 is then secreted and, on entering the gonad, it blocks apoptosis. These find-
ings yield insight into a novel pathway through which two single neurons regulate apoptotic fate in another tissue. Ultimately, this pathway links hy-

oxia to apoptosis. Knockdown of the TYR-2 ho-
mologue TRP2 in human melanoma cells increases basal and cisplatin-induced p53 apoptosis, indicat-
ing an evolutionary conserved function. TYR-2 would be a candidate target in new therapeutic strategies [117].

6 Metabolic diseases

The O-GlcNAc signaling pathway, one of the most evolutionary ancient pathways, couples the nutrient-dependent synthesis of UDP-GlcNAc to O-GlcNAc modification of Ser/Thr residues of a large number of nuclear and cytoplasmic protein targets. Accumulating data suggest the involvement of O-GlcNAc cycling in age-associated human diseases such as insulin resistance, X-linked dystonia parkinsonism, cancer and disease of the immune system.

Two highly conserved enzymes are responsible for the cycling of O-GlcNAc on Ser/Thr residues of target proteins: glycosyltransferase, OGT, and the O-GlcNAcase, which mediate the addition and the removal of O-GlcNAc, respectively. The identification of the enzymes involved in O-GlcNAc cycling led to the detection of their interacting partners. Two-hybrid screens reveal diverse proteins associated with vesicle and organelle movements in neurons, mitochondrial movement, or factors involved in the control of gene expression that interact with OGT. In C. elegans, two-hybrid analysis indicates the interaction of OGT-1 with the MAP kinase, PMK-1. The highly conserved hexosamine biosynthetic pathway is upstream of O-GlcNAc cycling. Accumulating findings suggested a link between the hexosamine biosynthetic pathway, O-GlcNAc cycling and mammalian insulin resistance [118].

C. elegans strains with putative null alleles of ogt-1 (ortholog of O-GlcNAc transferase) or oga-1 (ortholog of O-GlcNAcase) provide versatile platforms for studying the role of O-GlcNAc in cellular signaling and metabolism. Nuclear transport of transcription factors is normal in homozygous ogt-1(ok430) [119] and oga-1(ok1207) knockout animals [120], yet the ogt-1(ok430) mutant completely lacks any detectable O-GlcNAc on nuclear pore proteins, whereas the oga-1(ok1207) accumulated O-GlcNAc. Both mutant strains show increased glycogen and trehalose levels and decreased lipid storage. The link of human OGT and OGA to insulin resistance prompted the examination of the impact of ogt-1 and oga-1 deletions on the insulin-like-signaling pathway controlling nutrient storage, dauer formation, longevity and stress responses in C. elegans. oga-1(ok1207) knockout enhances dauer formation induced by a temperature-sensitive allele of the insulin-like receptor daf-2 (e1370) [120] under conditions in which the ogt-1(ok430) null allele lowers dauer formation [119]. C. elegans is the first animal with viable and fertile knockout alleles of OGA or OGT, which provide genetically amenable models of non-insulin-dependent diabetes. Use of O-GlcNAc cycling mutants in high-throughput RNAi screening revealed the interaction of ogt-1 with essential components of important signaling pathways such as β-catenin. In mammals, β-catenin triggers key developmental switches including the formation of T cells and B cells in adaptive immunity [121].

Accumulating evidence suggests that the enzymes of O-GlcNAc cycling may play a role in modulating transcription [122, 123]. The impact of null alleles of O-GlcNAc cycling genes on chromatin structure and gene expression can be globally examined in C. elegans. Whole-genome chromatin immunoprecipitation on-chip tiling arrays revealed over 800 promoters in which O-GlcNAc cycling occurs, including miRNA genes and multigene operons. Transcriptional profiling of O-GlcNAc knockout mutants confirmed the deregulation of numerous genes associated with insulin-like signaling, aging, stress response, innate immunity and carbohydrate/lipid metabolism [124]. These findings suggest that altered O-GlcNAc cycling has important implications in the diseases associated with aging, including obesity, type II diabetes mellitus, cardiovascular diseases, cancer and neurodegenerative diseases.

In C. elegans, insulin and its signaling pathway are implicated in the regulation of fat storage and reproduction and in modulating lifespan. daf-2, the homologue of the mammalian insulin receptor, is part of a signal transduction cascade homologous to the insulin pathway in mammals. DAF-2 knockout induces dauer formation and extends lifespan. Restoration of DAF-2 function specifically in neurons is sufficient to restore lifespan and reproduction of daf-2 knockouts to wild-type levels. Growing evidence suggests that impaired insulin signaling in the central nervous system plays a fundamental role in the pathogenesis of common metabolic diseases, including obesity and type II diabetes [125].

C. elegans provides a versatile platform for dissecting the molecular mechanisms underlying glucose-mediated impact on cellular and mitochondrial function in diabetes. An intracellular glucose concentration of 14 mmol/L, which is within the range observed in poorly controlled diabetes patients, results in methylglyoxal-derived modifications of mitochondrial proteins and increase in ROS formation, thus reducing lifespan in C. elegans. These effects are independent of osmotic pressure and the pathways activated by caloric re-
<table>
<thead>
<tr>
<th>Disease</th>
<th>Disease-associated protein</th>
<th>Characteristic pathology in <em>C. elegans</em></th>
<th><em>C. elegans</em> findings with potential therapeutic relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD-relevant tau</td>
<td>PHP-tau</td>
<td>Insoluble highly phosphorylated tau aggregates in neurons linked to a defective pattern of motor neuron development [25]</td>
<td>TOR-2 mediated suppression of polyQ aggregation [36]</td>
</tr>
<tr>
<td>PG</td>
<td>polyQ aggregates</td>
<td>Muscle (polyQm)[32] or neuronal (polyQn) [33] induced toxicity</td>
<td>Rescue of disease phenotype by ubiquilin overexpression[38] Amelioration of the motility defect by Drp-1 knockdown [39] Suppression of proteotoxicity by DR [41]</td>
</tr>
<tr>
<td>HD</td>
<td>Expression of human Htt (Q&gt;40) in body wall muscle</td>
<td>Motility defects [38]</td>
<td>Rescue of disease phenotype by ubiquilin overexpression [38] Amelioration of the motility defect by Drp-1 knockdown [39] Suppression of proteotoxicity by DR [41]</td>
</tr>
<tr>
<td>ALS</td>
<td>SOD1</td>
<td>Pan-neuronal expression caused severe locomotion defect [61]</td>
<td>smn-1(ok355) deletion mutant as a useful platform for functional analysis of human SMN protein [77]</td>
</tr>
<tr>
<td>SMA</td>
<td>SMN/SMN-1</td>
<td>Late larval arrest, decreased lifespan, defects in motility and pharyngeal pumping [76]</td>
<td></td>
</tr>
<tr>
<td>Stroke – Excitotoxicity</td>
<td>Specific ion channels (DEG-1, MEC-4, DEG-3, GSA-1 in nematode) Specific proteases (calpains CLP-1, TRA-3 and aspartyl proteases ASP-3, ASP-4 in nematode)</td>
<td>Neurodegeneration [80, 81]</td>
<td>Inhibition of executioner proteases (ASP-3, ASP-4) suppresses necrosis [81] Alterations of lysosome biogenesis and function by genetic or pharmacological treatment could affect necrotic cell death [84]</td>
</tr>
<tr>
<td>DMD</td>
<td>Dystrofin/dys-1</td>
<td>Muscle degeneration [90, 91]</td>
<td>chn-1/CHIP elimination in the musculature suppresses muscle degeneration [92]</td>
</tr>
<tr>
<td>OPMD</td>
<td>PABPN1</td>
<td>Muscle cell decline and abnormal motility [97]</td>
<td>Treatment with sirtuin inhibitors protect against mutant PABPN1 [97, 128]</td>
</tr>
</tbody>
</table>
miRNAs have also been implicated in the regulation of glucose and lipid metabolism, and hence in the initiation and progression of diabetes and its specific complications. miRNAs that play a critical role in the pathogenesis of the disease may serve as potential biomarkers for prognosis and diagnosis of diabetes. Furthermore, the altered expression profiles of miRNAs in the pancreas and insulin-targeted tissues in diabetic patients could provide insights for treating this complex metabolic disease [127].

7 Concluding remarks

Accumulating evidence demonstrates that most of the important pathways such as insulin signaling, Ras/Notch signaling, p53, and many miRNAs have remained essentially unchanged during evolution. Many human diseases, including cancer, originate from mutations in genes functioning in pathways conserved in C. elegans. Although nematode disease models might not perfectly recapitulate the pathophysiology of human disease, the small, transparent worm enables the use of powerful genetic and molecular approaches to dissect the toxicity mechanisms and determine the in vivo factors that exacerbate or cure pathological conditions. Table 1 summarizes a selection of human disease models in C. elegans. Besides being an excellent model for drug target identification, C. elegans is amenable to high-throughput screens for rapid and inexpensive drug evaluation before embarking on expensive and elaborate animal models.

Table 1. Continued

<table>
<thead>
<tr>
<th>Disease</th>
<th>Disease-associated protein</th>
<th>Characteristic pathology in C. elegans</th>
<th>C. elegans findings with potential therapeutic relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td>let-60/ras oncogenes</td>
<td></td>
<td>Apoptotic defects interfere with tumorigenesis and resistance to chemotherapeutic drugs [114]</td>
<td></td>
</tr>
<tr>
<td>vav-1/Vav</td>
<td></td>
<td>Anti-apoptotic factor, antagonizes p53/cep-1, interferes with tumor progression and therapy [117]</td>
<td></td>
</tr>
<tr>
<td>cep-1/p53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIFa/HIF-1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolic diseases</td>
<td>ogt-1, oga-1</td>
<td>Null mutations cause alterations in carbohydrate and lipid metabolism [119, 120, 124]</td>
<td>Overexpression or inhibition of specific miRNAs may be a future tool for targeting diabetes [127]</td>
</tr>
<tr>
<td>(insulin resistance, type II diabetes)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

striction in eat-2 mutants and the insulin-like receptor daf-2/daf-16 pathway. Conversely, high glucose-mediated lifespan reduction in C. elegans is dependent on glyoxalase-1-controlled mitochondrial complexes II and III. Further studies should delineate the relevance of these mechanisms described in C. elegans to the situation in diabetic patients [126].

8 References


[100] Ferrari, R., Di Renzo, M. F., Scotlandi, K., Baldini, N. et al., The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. *Oncogene* 1995, 10, 739–749.